395 related articles for article (PubMed ID: 26716505)
1. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
[TBL] [Abstract][Full Text] [Related]
2. [Expression of CCDC67 mRNA and its role in patients with papillary thyroid carcinoma].
Yin D; Xu J; Wang Y; Li H; Zhang Y; Jiang J; Wang Q
Zhonghua Yi Xue Za Zhi; 2014 Aug; 94(30):2382-5. PubMed ID: 25399985
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin levels in patients with papillary thyroid cancer according to the presence of Hashimoto's thyroiditis.
Park SH; Park CS; Kim YI; Nam-Goong IS; Kim YS; Lee JC; Choi JI; Park JW; Kim ES
Asian Pac J Cancer Prev; 2015; 16(6):2447-51. PubMed ID: 25824779
[TBL] [Abstract][Full Text] [Related]
4. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.
Liao T; Qu N; Shi RL; Guo K; Ma B; Cao YM; Xiang J; Lu ZW; Zhu YX; Li DS; Ji QH
Oncotarget; 2017 Jan; 8(1):238-247. PubMed ID: 27462868
[TBL] [Abstract][Full Text] [Related]
5. MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67.
Liu ZM; Wu ZY; Li WH; Wang LQ; Wan JN; Zhong Y
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3421-3430. PubMed ID: 31081096
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
7. PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms.
Nicolussi A; D'Inzeo S; Mincione G; Buffone A; Di Marcantonio MC; Cotellese R; Cichella A; Capalbo C; Di Gioia C; Nardi F; Giannini G; Coppa A
Int J Oncol; 2014 Feb; 44(2):548-56. PubMed ID: 24316730
[TBL] [Abstract][Full Text] [Related]
8. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
[TBL] [Abstract][Full Text] [Related]
9. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
10. A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.
Occhi G; Barollo S; Regazzo D; Bertazza L; Galuppini F; Guzzardo V; Jaffrain-Rea ML; Vianello F; Ciato D; Ceccato F; Watutantrige-Fernando S; Bisognin A; Bortoluzzi S; Pennelli G; Boscaro M; Scaroni C; Mian C
Oncotarget; 2015 Oct; 6(31):32104-14. PubMed ID: 26392334
[TBL] [Abstract][Full Text] [Related]
11. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.
Hu S; Liu D; Tufano RP; Carson KA; Rosenbaum E; Cohen Y; Holt EH; Kiseljak-Vassiliades K; Rhoden KJ; Tolaney S; Condouris S; Tallini G; Westra WH; Umbricht CB; Zeiger MA; Califano JA; Vasko V; Xing M
Int J Cancer; 2006 Nov; 119(10):2322-9. PubMed ID: 16858683
[TBL] [Abstract][Full Text] [Related]
12. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
13. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
14. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
16. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
17. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-146a targets PRKCE to modulate papillary thyroid tumor development.
Zhang X; Li D; Li M; Ye M; Ding L; Cai H; Fu D; Lv Z
Int J Cancer; 2014 Jan; 134(2):257-67. PubMed ID: 23457043
[TBL] [Abstract][Full Text] [Related]
19. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
20. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]